Novanta NOVT Medical Solutions — Restructuring Charges And Acquisition Related Costs
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Novanta in its filing.
Tagged under the XBRL concept novt:RestructuringChargesAndAcquisitionRelatedCosts.
The official record: Novanta’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Novanta's medical solutions — restructuring charges and acquisition related costs.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Novanta's medical solutions — restructuring charges and acquisition related costs?
- Novanta (NOVT) reported medical solutions — restructuring charges and acquisition related costs of $1.24M in Q1 2026.
- How has Novanta's medical solutions — restructuring charges and acquisition related costs changed year-over-year?
- Novanta's medical solutions — restructuring charges and acquisition related costs increased by 1152.5% year-over-year, from $99K to $1.24M.
- What is the long-term trend for Novanta's medical solutions — restructuring charges and acquisition related costs?
- Over 3 years (2022 to 2025), Novanta's medical solutions — restructuring charges and acquisition related costs has grown at a 206.6% compound annual growth rate (CAGR), from $432K to $12.45M.
- What does medical solutions — restructuring charges and acquisition related costs mean?
- These are non-recurring expenses associated with organizational realignment, facility consolidations, or the integration of acquired businesses. Tracking these costs allows investors to isolate core operational performance from temporary or strategic transformation activities. High levels of these charges may indicate significant ongoing business integration or structural shifts.